Mereo BioPharma Group PLC American
$0.30 +$0.01 (+4.97%) 1D Market openKey Metrics
The Story So Far
LAST 6 MONTHS PRIMARY SOURCES ONLY-
Jul 16
Money rotated out of high-beta cohorts market-wide.
High-beta names lagged the blue-chips by 20.3 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.
RECEIPT: ROTATION GAUGE, LIVE -
May 26
The stock moved +19.9% in a single session.
Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.
RECEIPT: DAILY BAR, May 26 -
May 20
The stock moved +18.8% in a single session.
Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.
RECEIPT: DAILY BAR, May 20 -
May 6
From its Jan 30 high, the share price fell 46%.
Peak close $0.44 on Jan 30; trough close $0.24 on May 6. The drawdown is the fact — the chapters around it are the context.
RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -46%
The story updates itself as events post · The wolf reports; you decide
Snapshot
About Mereo BioPharma Group PLC American
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases.
Wolf Grade COMING SOON
The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.